Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
ESOMEPRAZOLE
AstraZeneca UK Limited
A02BC05
ESOMEPRAZOLE
10 Milligram
Granules for Oral Suspension
Product subject to prescription which may be renewed (B)
esomeprazole
Not Marketed
2008-08-01
566505-A01 22-03-17 PS10335 AZL4008B 7520 BL Nexium 10mg Leaflet: Combined UK Black Technical Info Profile BODY TEXT SIZE 9.5 pt SMALLEST TEXT SIZE 6.0 pt Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What Nexium is and what it is used for 2. What you need to know before you take Nexium 3. How to take Nexium 4. Possible side effects 5. How to store Nexium 6. Contents of the pack and other information 1. What Nexium is and what it is used for Nexium contains a substance called esomeprazole. This belongs to a group of medicines called proton pump inhibitors. These work by reducing the amount of acid that your stomach produces. Nexium is used to treat the following conditions: _Children over 1 year of age _ Nexium is used to treat a condition called “gastroesophageal reflux disease” (GERD). • This is where acid from the stomach escapes into the gullet (esophagus) causing pain, inflammation and heartburn. Heartburn is a burning feeling rising from the stomach or lower chest up towards the neck. • In children, the symptoms of the condition can include the return of stomach contents into the mouth (regurgitation), being sick (vomiting) and poor weight gain. _Children over 4 years of age_ • Ulcers which are infected with bacteria called ‘_Helicobacter pylori’_. If your child has this condition, your doctor may also prescribe antibiotics to treat the infection and allow the ulcer to heal. 2. What you need to know before you take Nexium Do not take Nexium: • If you are allergic to esomeprazole or o Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Nexium 10 mg gastro-resistant granules for oral suspension, sachet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains: 10 mg esomeprazole (as magnesium trihydrate). Excipient(s) with known effect Each sachet contains 6.8 mg sucrose and 2.8 g glucose For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Gastro-resistant granules for oral suspension, sachet. Pale yellow fine granules. Brownish granules may be visible. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Nexium oral suspension is primarily indicated for: Paediatric population _Children 1-11 years old_ _Gastroesophageal Reflux Disease (GERD)_ - treatment of endoscopically proven erosive reflux esophagitis - symptomatic treatment of gastroesophageal reflux disease (GERD) _Children over 4 years of age_ In combination with antibiotics in treatment of duodenal ulcer caused by_ Helicobacter pylori_. _Adults and adolescents from the age of 12 years_ For indications in patients from the age of 12 years reference is made to the Nexium gastro-resistant tablet SmPC. Nexium oral suspension may also be used by patients having difficulty swallowing dispersed Nexium gastro-resistant tablets. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Paediatric population _CHILDREN 1 – 11 YEARS WITH A BODYWEIGHT OF_ _10 KG_ _Gastroesophageal Reflux Disease (GERD)_ _- Treatment of endoscopically proven erosive reflux esophagitis_ Weight 10- <20 kg: 10 mg once daily for 8 weeks. Weight 20 kg: 10 mg or 20 mg once daily for 8 weeks. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ __ Read the complete document